325 related articles for article (PubMed ID: 9733666)
1. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
[TBL] [Abstract][Full Text] [Related]
2. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists.
Hamelin BA; Bouayad A; Drolet B; Gravel A; Turgeon J
Drug Metab Dispos; 1998 Jun; 26(6):536-9. PubMed ID: 9616188
[TBL] [Abstract][Full Text] [Related]
4. Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes.
Nakamura K; Yokoi T; Kodama T; Inoue K; Nagashima K; Shimada N; Shimizu T; Kamataki T
J Pharmacol Exp Ther; 1998 Feb; 284(2):437-42. PubMed ID: 9454781
[TBL] [Abstract][Full Text] [Related]
5. Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes.
Springer D; Paul LD; Staack RF; Kraemer T; Maurer HH
Drug Metab Dispos; 2003 Aug; 31(8):979-82. PubMed ID: 12867484
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine.
Kishimoto W; Hiroi T; Sakai K; Funae Y; Igarashi T
Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):273-92. PubMed ID: 9485522
[TBL] [Abstract][Full Text] [Related]
7. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen.
Dong H; Haining RL; Thummel KE; Rettie AE; Nelson SD
Drug Metab Dispos; 2000 Dec; 28(12):1397-400. PubMed ID: 11095574
[TBL] [Abstract][Full Text] [Related]
8. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
Fischer V; Vickers AE; Heitz F; Mahadevan S; Baldeck JP; Minery P; Tynes R
Drug Metab Dispos; 1994; 22(2):269-74. PubMed ID: 8013282
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
10. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
11. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal SS; Kupfer D
Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
[TBL] [Abstract][Full Text] [Related]
14. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
[TBL] [Abstract][Full Text] [Related]
16. Effect of sodium ozagrel on the activity of rat CYP2D6.
Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
19. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
Yu A; Dong H; Lang D; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
[TBL] [Abstract][Full Text] [Related]
20. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
